Tech Company Financing Transactions
Trevi Therapeutics Funding Round
TPG Biotech joined a $10 million Series A venture round for Trevi Therapeutics. This VC investment round was announced on 12/19/2012.
Transaction Overview
Company Name
Announced On
12/19/2012
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
TPG Biotech (Eran Nadav)
Proceeds Purpose
With the proceeds from the Series A investment, Trevi intends to advance T111, an oral extended release opioid with a unique agonist/antagonist mechanism of action, into clinical development for the treatment of uremic pruritus.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
195 Church St. 14th Floor
New Haven, CT 06510
USA
New Haven, CT 06510
USA
Phone
Website
Email Address
Overview
Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jennifer Good
Chief Financial Officer
Christopher Seiter
Chief Medical Officer
Thomas Sciascia
Vice President
Amale Hawi
VP - Bus. Development
Helena Brett-Smith
VP - Bus. Development
Yann Mazabraud
Browse more venture capital transactions:
Prev: 12/19/2012: Tubular Labs venture capital transaction
Next: 12/19/2012: Catbird venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs